Houlihan Lokey Advises MLase AG

Houlihan Lokey is pleased to announce that MLase AG, a market-leading CDMO of high-quality excimer lasers for medical devices, has been acquired by Maxburg Capital Partners GmbH (Maxburg). The transaction closed on 16 August 2023.

MLase, based in Germering, Germany, and founded in 2007, is a leading developer, manufacturer, and distributor of high-quality compact UV lasers, specifically excimer lasers, for leading medical blue-chip OEM companies and industrial companies around the world. These lasers are known for their high reliability, homogeneous beam profile, and energy stabilisation, making them ideal for demanding applications. MLase’s excimer lasers are used in medical devices for laser treatments of visual impairments for refractive errors, severe glaucoma cases that require laser surgery to reduce intraocular pressure, and minimally invasive interventional procedures within the (cardio-) vascular system. The company’s innovative approach, customised products, and commitment to quality have positioned it as a trusted and leading provider in the excimer laser technology market.

Maxburg is a management- and partner-owned investment management company headquartered in Munich, Germany, with a total fund volume and capital commitments of €600 million. Maxburg is focused on the German-speaking region and acquires operationally stable and cash-flow producing SMEs, and since inception in 2014, has completed 22 investments across Germany and bordering geographies.

Maxburg commented, “In partnership with MLase’s management, our aim is to foster the continuous growth of the company. We plan to expand the product portfolio while building upon MLase’s strong reputation as a med-tech CDMO committed to the highest quality and service excellence.”

Houlihan Lokey served as the exclusive financial advisor to the founders and shareholders of MLase and assisted in marketing the transaction, managing the transaction process and negotiating the financial aspects of the transaction on their behalf. This transaction further enhances Houlihan Lokey’s extensive track record in the medtech sector.